Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Pharmacology
• Cancer Therapeutics

Background:

• Advances in non-small cell lung cancer (NSCLC) treatment, particularly epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), have improved patient outcomes.
• These targeted therapies are effective for patients with specific EGFR-activating mutations.
• However, EGFR TKIs are associated with distinct side effects not typically observed with traditional chemotherapy or radiotherapy.

Purpose of the Study:

• To review the pathogenesis of adverse events associated with EGFR TKI therapy in NSCLC.
• To provide evidence-based management strategies for these toxicities.
• To aid healthcare practitioners in optimizing patient care and treatment benefit.

Main Methods:

• Literature review of studies on EGFR TKI mechanisms of action and associated toxicities.
• Synthesis of information regarding the pathogenesis of common side effects.
• Compilation of current management guidelines and strategies.

Main Results:

• EGFR TKIs can cause unique adverse effects including rash, diarrhea, mucositis/stomatitis, paronychia, ocular disorders, and interstitial lung disease.
• These toxicities are linked to the drugs' targeted mechanism of action.
• Effective management strategies are crucial for patient adherence and treatment success.

Conclusions:

• Understanding the mechanism-based toxicities of EGFR TKIs is essential for managing NSCLC patients.
• Proactive and specific management of side effects can help patients tolerate treatment and achieve better outcomes.
• This review offers guidance for advanced practitioners to maximize the benefits of EGFR TKI therapy.